Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Convergent action on AMR identified as an important area of intervention
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
The slogan for this year's World Blood Donor Day campaign is 'Give blood, give plasma, share life, share often'
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg had annual sales of USD 13 mn in the United States
UTD2 is the world's first oral epothilone microtubule inhibitor
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
Subscribe To Our Newsletter & Stay Updated